Table 3 Characteristics of the blood donors identified with resistance-associated mutations.

From: HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China

Sample ID

Gender

Age

Donation

Ethnicity

Education

Genotype

PI accessory DRMs

PI major DRMs

NNRTI DRMs

Drug resistance

Henan-011

Male

24

First-time

Han

Associate degree

URF (PR-RT: CRF79_0107)

M46R

  

—

Henan-016

Male

46

Repeated

Han

Secondary school or below

CRF07_BC

Q58E

  

PLLR to NFV; LLR to TPV

Beijing-045

Male

34

Repeated

Han

Master/Bachelor degree

CRF07_BC

Q58E

  

PLLR to NFV; LLR to TPV

Shenzhen-010

Male

26

First-time

Han

Secondary school or below

CRF07_BC

Q58E

  

PLLR to NFV; LLR to TPV

Tongzhou-115

Male

29

First-time

Han

Associate degree

URF (PR-RT: B)

 

M46L

V106I

PLLR to ATV, FPV, IDV, LPV, SQV, TPV, ETR, NVP and RPV; LLR to NFV and DOR

Harbin-007

Male

19

First-time

Han

Master/Bachelor degree

CRF01_AE

 

M46I*

 

PLLR to ATV, FPV, IDV, LPV andSQV; IR to NFV

Shenzhen-011

Male

22

First-time

Han

Secondary school or below

CRF01_AE

 

N88S

 

HLR to ATV and NFV, LLR to IDV and SQV

Tongzhou-017

Male

31

First-time

Han

Associate degree

CRF07_BC

  

K101E*

IR to NVP and RPV; PLLR to DOR, EFV and ETR

Tongzhou-025

Male

53

First-time

Han

Associate degree

URF (PR-RT: CRF79_0107)

  

K103N*

HLR to EFV and NVP

Tongzhou-126

Male

39

First-time

Han

Associate degree

URF (PR-RT: CRF01_AE)

  

K103N*

HLR to EFV and NVP

Shenzhen-019

Male

31

First-time

Han

Master/Bachelor degree

CRF01_AE

  

V179D + K103R

IR to EFV and NVP; PLLR to ETR; LLR to RPV

Tongzhou-022

Male

43

First-time

Han

Associate degree

CRF65_cpx

  

V179D + K103R

IR to EFV and NVP; PLLR to ETR; LLR to RPV

Henan-005

Male

50

First-time

Han

Secondary school or below

URF (PR-RT: CRF07_BC)

  

V179D

PLLR to EFV, ETR, NVP and RPV

Henan-020

Male

35

First-time

Han

Secondary school or below

CRF07_BC

  

V179D

PLLR to EFV, ETR, NVP and RPV

Chongqing-008

Female

48

Repeated

Han

Secondary school or below

CRF07_BC

  

V179D

PLLR to EFV, ETR, NVP and RPV

Chongqing-015

Male

50

First-time

Han

Secondary school or below

CRF08_BC

  

V179D

PLLR to EFV, ETR, NVP and RPV

Changchun-066

Male

20

First-time

Han

Master/Bachelor degree

URF (PR-RT: CRF07_BC)

  

V179D

PLLR to EFV, ETR, NVP and RPV

Changchun-074

Male

24

First-time

Han

Associate degree

CRF01_AE

  

V179D

PLLR to EFV, ETR, NVP and RPV

Shaanxi-063-NAT

Male

28

First-time

Han

Secondary school or below

CRF07_BC

  

V179D

PLLR to EFV, ETR, NVP and RPV

Henan-019

Male

31

First-time

Han

Secondary school or below

URF (PR-RT: CRF55_01B)

  

V179E

PLLR to EFV, ETR, NVP and RPV

Chongqing-003

Male

57

Repeated

Han

Secondary school or below

CRF55_01B

  

V179E

PLLR to EFV, ETR, NVP and RPV

Chongqing-005

Male

26

First-time

Han

Secondary school or below

CRF08_BC

  

V179E

PLLR to EFV, ETR, NVP and RPV

Harbin-004

Male

29

Repeated

Han

Associate degree

B

  

V179E

PLLR to EFV, ETR, NVP and RPV

Harbin-022

Male

35

First-time

Han

Secondary school or below

URF (PR-RT: CRF55_01B)

  

V179E

PLLR to EFV, ETR, NVP and RPV

Shaanxi-022

Male

40

First-time

Han

Associate degree

CRF55_01B

  

V179E

PLLR to EFV, ETR, NVP and RPV

Shenzhen-012-2018

Male

29

First-time

Han

Secondary school or below

CRF55_01B

  

V179E

PLLR to EFV, ETR, NVP and RPV

Chongqing-011

Male

40

Repeated

Minority

Secondary school or below

CRF01_AE

  

V179T

—

Jiangsu-010

Male

39

First-time

Han

Associate degree

CRF01_AE

  

V179T

—

  1. *Sequences with surveillance drug-resistance mutations (SDRMs).
  2. 1. The interpretation system reports five different possible levels of drug resistance(https://hivdb.stanford.edu/): Susceptible, Potential low-level resistance (PLLR), Low-level resistance (LLR), Intermediate resistance (IR) and High-level resistance (HLR).
  3. 2. Unique recombinant form (URF); Protease Inhibitors (PIs): Atazanavir (ATV), Darunavir (DRV), Fosamprenavir (FPV), Indinavir (IDV),Lopinavir (LPV), Nelfinavir (NFV), Saquinavir (SQV), Tipranavir (TPV); Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Doravirine (DOR), Efavirenz (EFV), Etravirine (ETR), Nevirapine (NVP), Rilpivirine (RPV).
  4. 3. The combination of V179D and K103R defined as NNRTI DRM act synergistically to reduce EFV and NVP susceptibility.
  5. 4. M46R is a highly unusual mutation at this position, V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs, the details about drug resistance are not shown in Stanford University HIV DRUG RESISTANCE DATABASE (https://hivdb.stanford.edu/).
Back to article page